Duchenne Muscular Dystrophy Market to Witness Growth by 2032, Estimates DelveInsight | Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals, ReveraGen Biopharma, Roche/Sarep

DelveInsight's "Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Duchenne Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Duchenne Muscular Dystrophy Market Forecast
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Duchenne Muscular Dystrophy Market Report:
• The Duchenne Muscular Dystrophy market size was valued approximately USD 1,700 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2032, the estimated number of prevalent cases of Duchenne Muscular Dystrophy (DMD) in the seven major markets (7MM) was approximately 34,000.
• In 2022, within the United States, the greatest percentage of cases specific to particular age groups were noted in the range of 5 to 9 years old, followed by the age brackets of 10 to 14 years and 15 to 20 years.
• In the United States, among individuals diagnosed with Duchenne Muscular Dystrophy (DMD), the highest recorded prevalence of associated comorbidities was observed in the case of Scoliosis, reaching approximately 4,000 cases in 2022.
• In the EU4 countries (Germany, France, Italy, and Spain) along with the United Kingdom, the highest prevalence of Duchenne Muscular Dystrophy (DMD) was observed in the UK, totaling approximately 3,000 cases in 2022. This was followed by Germany and France, whereas Spain had the lowest number of cases recorded in the same year.
• In the present US market, there are several approved products-EMFLAZA (deflazacort), VYONDYS 53 (golodirsen), EXONDYS 51 (eteplirsen), AMONDYS 45 (casimersen), and VILTEPSO (viltolarsen)-available for individuals with Duchenne Muscular Dystrophy (DMD). Within the EU4 countries and the UK, steroid therapies dominate the current market, accompanied by an approved medication designed for DMD patients with the nonsense mutation, TRANSLARNA (ataluren). However, in Japan, the sole approved treatment available is VILTEPSO (viltolarsen).
• Key Duchenne Muscular Dystrophy Companies: Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others
• Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others
• The Duchenne Muscular Dystrophy epidemiology based on gender analyzed that Duchenne Muscular Dystrophy rarely affects females
• The Duchenne Muscular Dystrophy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.

Duchenne Muscular Dystrophy Overview
Duchenne Muscular Dystrophy (DMD) is a genetic disorder characterized by progressive muscle weakness and degeneration.

Get a Free sample for the Duchenne Muscular Dystrophy Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Duchenne Muscular Dystrophy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Duchenne Muscular Dystrophy Epidemiology Segmentation:
The Duchenne Muscular Dystrophy market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Duchenne Muscular Dystrophy
• Prevalent Cases of Duchenne Muscular Dystrophy by severity
• Gender-specific Prevalence of Duchenne Muscular Dystrophy
• Diagnosed Cases of Episodic and Chronic Duchenne Muscular Dystrophy

Download the report to understand which factors are driving Duchenne Muscular Dystrophy epidemiology trends @ Duchenne Muscular Dystrophy Epidemiology Forecast
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr


Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Duchenne Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Duchenne Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Duchenne Muscular Dystrophy Therapies and Key Companies
• Givinostat (ITF2357): Italfarmaco
• ATL1102: Antisense Therapeutics
• SRP-9001: Sarepta Therapeutics
• Vamorolone: Santhera Pharmaceuticals/ReveraGen Biopharma
• PF06939926: Pfizer
• Pamrevlumab: FibroGen
• CAP-1002: Capricor Therapeutics
• Pamrevlumab: Fibrogen
• Delandistrogene moxeparvovec: Roche/Sarepta Therapeutics
• EDG 5506: Edgewise Therapeutics
• WVE N531: Wave Life Sciences Ltd
• PGN EDO51: PepGen
• UX810: Ultragenyx Pharmaceutical

Discover more about therapies set to grab major Duchenne Muscular Dystrophy market share @ Duchenne Muscular Dystrophy Treatment Landscape
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Duchenne Muscular Dystrophy Market Strengths
• The pipeline of DMD is robust with the advent of several potential products in late-stage of clinical development.
• Several new therapies have been approved for the treatment of DMD recently, even Japan has witnessed the launch of VILTEPSO now.

Duchenne Muscular Dystrophy Market Opportunities
• Wider commercial opportunity for therapies such as Capricor's CAP-1002 and Antisense's ATL1102, which are specifically focusing on improving upper limb functions in DMD patients and are targeting a much larger patient segment when compared to the Exon-Skipping therapies.

Scope of the Duchenne Muscular Dystrophy Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Duchenne Muscular Dystrophy Companies: Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others
• Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others
• Duchenne Muscular Dystrophy Therapeutic Assessment: Duchenne Muscular Dystrophy current marketed and Duchenne Muscular Dystrophy emerging therapies
• Duchenne Muscular Dystrophy Market Dynamics: Duchenne Muscular Dystrophy market drivers and Duchenne Muscular Dystrophy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Duchenne Muscular Dystrophy Unmet Needs, KOL's views, Analyst's views, Duchenne Muscular Dystrophy Market Access and Reimbursement

To know more about Duchenne Muscular Dystrophy companies working in the treatment market, visit @ Duchenne Muscular Dystrophy Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Duchenne Muscular Dystrophy Market Report Introduction
2. Executive Summary for Duchenne Muscular Dystrophy
3. SWOT analysis of Duchenne Muscular Dystrophy
4. Duchenne Muscular Dystrophy Patient Share (%) Overview at a Glance
5. Duchenne Muscular Dystrophy Market Overview at a Glance
6. Duchenne Muscular Dystrophy Disease Background and Overview
7. Duchenne Muscular Dystrophy Epidemiology and Patient Population
8. Country-Specific Patient Population of Duchenne Muscular Dystrophy
9. Duchenne Muscular Dystrophy Current Treatment and Medical Practices
10. Duchenne Muscular Dystrophy Unmet Needs
11. Duchenne Muscular Dystrophy Emerging Therapies
12. Duchenne Muscular Dystrophy Market Outlook
13. Country-Wise Duchenne Muscular Dystrophy Market Analysis (2019-2032)
14. Duchenne Muscular Dystrophy Market Access and Reimbursement of Therapies
15. Duchenne Muscular Dystrophy Market Drivers
16. Duchenne Muscular Dystrophy Market Barriers
17. Duchenne Muscular Dystrophy Appendix
18. Duchenne Muscular Dystrophy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Duchenne Muscular Dystrophy Epidemiology https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Duchenne Muscular Dystrophy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Duchenne Muscular Dystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.